Quest Partners LLC Invests $265,000 in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Quest Partners LLC bought a new position in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) during the 3rd quarter, Holdings Channel reports. The institutional investor bought 2,855 shares of the medical instruments supplier’s stock, valued at approximately $265,000.

Several other institutional investors have also recently added to or reduced their stakes in the business. Victory Capital Management Inc. raised its holdings in LeMaitre Vascular by 23.3% during the third quarter. Victory Capital Management Inc. now owns 53,060 shares of the medical instruments supplier’s stock worth $4,929,000 after purchasing an additional 10,011 shares in the last quarter. Nations Financial Group Inc. IA ADV grew its position in shares of LeMaitre Vascular by 8.8% in the 3rd quarter. Nations Financial Group Inc. IA ADV now owns 22,080 shares of the medical instruments supplier’s stock valued at $2,051,000 after buying an additional 1,787 shares during the last quarter. GDS Wealth Management acquired a new stake in LeMaitre Vascular during the 3rd quarter worth $205,000. Los Angeles Capital Management LLC lifted its position in LeMaitre Vascular by 23.1% in the third quarter. Los Angeles Capital Management LLC now owns 33,656 shares of the medical instruments supplier’s stock valued at $3,126,000 after acquiring an additional 6,320 shares during the last quarter. Finally, Atria Investments Inc boosted its stake in LeMaitre Vascular by 43.9% in the third quarter. Atria Investments Inc now owns 8,853 shares of the medical instruments supplier’s stock valued at $822,000 after acquiring an additional 2,701 shares in the last quarter. Hedge funds and other institutional investors own 84.64% of the company’s stock.

LeMaitre Vascular Stock Performance

Shares of LMAT opened at $105.43 on Wednesday. The stock has a market capitalization of $2.37 billion, a P/E ratio of 57.61, a P/E/G ratio of 2.64 and a beta of 0.89. LeMaitre Vascular, Inc. has a 1 year low of $51.70 and a 1 year high of $109.58. The company’s fifty day moving average is $94.52 and its two-hundred day moving average is $87.42.

LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings results on Thursday, October 31st. The medical instruments supplier reported $0.49 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.44 by $0.05. The business had revenue of $54.82 million for the quarter, compared to analyst estimates of $53.50 million. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. The business’s revenue was up 15.6% compared to the same quarter last year. During the same period in the previous year, the business posted $0.33 earnings per share. Sell-side analysts predict that LeMaitre Vascular, Inc. will post 1.94 EPS for the current year.

LeMaitre Vascular Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, December 5th. Stockholders of record on Thursday, November 21st will be issued a $0.16 dividend. The ex-dividend date is Thursday, November 21st. This represents a $0.64 annualized dividend and a dividend yield of 0.61%. LeMaitre Vascular’s dividend payout ratio is currently 34.97%.

Analyst Ratings Changes

A number of analysts have recently commented on the company. JMP Securities lifted their target price on LeMaitre Vascular from $77.00 to $100.00 and gave the stock a “market outperform” rating in a research report on Tuesday, August 20th. Cantor Fitzgerald initiated coverage on LeMaitre Vascular in a research note on Tuesday, October 15th. They issued a “neutral” rating and a $96.00 price objective for the company. Barrington Research raised their target price on shares of LeMaitre Vascular from $92.00 to $93.00 and gave the stock an “outperform” rating in a research report on Friday, November 1st. StockNews.com cut shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Thursday, November 21st. Finally, Lake Street Capital began coverage on shares of LeMaitre Vascular in a research note on Friday, August 2nd. They set a “buy” rating and a $105.00 price target for the company. Three analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $94.57.

Insider Activity at LeMaitre Vascular

In other LeMaitre Vascular news, Director Bridget A. Ross sold 3,750 shares of the firm’s stock in a transaction on Friday, November 15th. The stock was sold at an average price of $101.47, for a total value of $380,512.50. Following the completion of the sale, the director now owns 2,278 shares of the company’s stock, valued at approximately $231,148.66. This trade represents a 62.21 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 10.79% of the company’s stock.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.